Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
SOUTH SAN FRANCISCO, Calif.,, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage bi...
Barclays analyst Etzer Darout initiates coverage on Corvus Pharma (NASDAQ:CRVS) with a Overweight rating and announces Price...
Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.13)...
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the IND applicatio...
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced preclinical data highli...
Cohort 3 demonstrates earlier and deeper responses compared to cohorts 1-2All three cohorts show separation from placebo with s...
Mizuho analyst Graig Suvannavejh maintains Corvus Pharma (NASDAQ:CRVS) with a Outperform and lowers the price target from $1...
Oppenheimer analyst Jeff Jones reiterates Corvus Pharma (NASDAQ:CRVS) with a Outperform and raises the price target from $15...
